All posts

MGRO stock soars on Bayer deal

Shares of MustGrow Biologics (MustGrow Biologics Stock Quote, Chart, News, Analysts, Financials TSXV:MGRO) are leading the TSXV today after the company inked a deal with Bayer.

The deal centres around MGRO’s mustard-based biocontrol tech. The Saskatchewan-based company designs biocontrol and biofertility products that hardness the natural defense mechanisms of the mustard plant.

“MustGrow is thrilled to commercialize our technologies with Bayer in three important food producing regions. Through Bayer’s research, development and commercial teams we have seen a rapid advancement in our product and market knowledge in the last two years,” said CEO Corey Giasson. “Working with the leader in global crop science and sustainable agriculture is a tremendous opportunity for our organization to see our mustard plant-based technologies commercialized globally.”

Under the terms of the agreement, MustGrow will will receive an upfront payment, plus milestone-related bonuses. The company says the deal could be worth as much as (US) $35 to $40-million.

“Biologicals are part of an exciting frontier that offers new solutions for the challenges that growers face across the world,” Benoit Hartmann, Head of Biologics for Bayer said. “We’re committed to working with leading innovators like Mustgrow to accelerate the development of innovative biological solutions that provide safe, sustainable options for farmers and are looking forward to continuing our work together.”

At press time, shares of MGRO were up 38.1 per cent to $1.45.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: MGRO
Staff

Recent Posts

Is Dexterra Group a buy?

Its first quarter results are in the books and Beacon analyst Kirk Wilson has lowered his price target on Dexterra… [Read More]

2 hours ago

Is AYR stock a buy?

Following the company's first quarter results, Beacon analyst Russell Stanley has maintained his "Buy" rating on Ayr Wellness (Ayr Wellness… [Read More]

12 hours ago

Cresco Labs earns target raise at Echelon

Following the company's first quarter results, Echelon Capital Markets analyst Andrew Semple has raised his price target on Cresco Labs… [Read More]

13 hours ago

SSTI is a buy, Roth says

Its first quarter results are in the book and Roth MKM analyst Richard K Baldry is still bullish on SoundThinking… [Read More]

1 day ago

GLXY wins price target raise at ATB Capital

Following the company's first quarter results, ATB Capital Markets analyst Martin Toner has raised his price target on Galaxy Digital… [Read More]

1 day ago

Paradigm cuts price target on TTNM

Following first quarter results he describes as "mixed" Paradigm Capital analyst Alexandra Ricci has cut her price target on Titanium… [Read More]

2 days ago